Why the study?
Does rosiglitazone prevent cardiac dysfunction and mortality in LPS-treated mice?
Population
C57BL/6 wild-type mice and αMHC-PPARγ transgenic mice treated with Escherichia coli lipopolysaccharide to…
Comparison
Rosiglitazone (PPARγ agonist) vs WY-14643 and/or untreated LPS-exposed controls
Design
Preclinical
Authors
Loading...
Hypothesis-generating for PPARγ agonism in sepsis cardiomyopathy; prospective human trials needed before any clinical consideration.
Does rosiglitazone prevent cardiac dysfunction and mortality in LPS-treated mice?
PPARγ activation prevents sepsis-related cardiac dysfunction and mortality in mice, suggesting a potential therapeutic target for sepsis-induced cardiomyopathy.
Drosatos et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: